

# THE SWEDISH MEDICAL PRODUCTS AGENCY

Clinical trials – Licences  
Maria Lüttgen/is

## Decision

Date: 8 August 2014

EU no. 2011-006130-16

Ref. 5.1-2014-43006

Dr Veronica Murray  
Karolinska Institutet  
Danderyd Hospital  
182 88 Stockholm

### **Permission for clinical pharmaceutical study**

*Clinical study of Oxatin (fluoxetine) (EFFECTS2012)*

You have applied for permission to carry out a clinical pharmaceutical study.

Pursuant to § 14 of the Swedish Pharmaceuticals Act (1992:859), the Swedish Medical Products Agency grants permission to carry out the clinical pharmaceutical study.

In accordance with LVFS 2011:19, a decision from the Ethical Review Board should be sent to the Swedish Medical Products Agency no later than 15 days from the day on which the sponsor receives notice of the decision.

On behalf of the Swedish Medical Products Agency

Maria Lüttgen  
Specialist Physician

This decision document is not signed. This does not affect the validity of the decision.

Translated by



Språkservice

Reference: NKZ70

Malmö, Sweden: 20170920

Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN  
Visiting address: Dag Hammarskjölds väg 42, Uppsala  
Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66  
Internet: [www.lakemedelsverket.se](http://www.lakemedelsverket.se) E-mail: [registrator@mpa.se](mailto:registrator@mpa.se)

Translated by



Reference: NKZ70

Malmö, Sweden: 20170920